{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-018743","form_type":"8-K","ticker":"MLAB","cik":"0000724004","company_name":"MESA LABORATORIES INC /CO/","filed_at":"2022-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:58.018897+00:00","generated_at":"2026-06-24T04:36:51.331263+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mesa Labs Q1: revenue up 44% but net loss of $1.4M; organic growth slows to 3%","bullets":["GAAP diluted EPS loss of ($0.27) vs prior-year EPS of $0.38; net loss of ($1.438M) from $1.995M income.","Revenue $50.5M (+44% total, +3% organic); non-GAAP adjusted OI $6.158M (-33%) or $1.17/share.","Clinical Genomics (29% rev) hit by China lockdowns; Sterilization & Disinfection down 2%.","Biopharma Development grew 24%; Calibration Solutions fell 6% on supply chain shortages.","Unusual items: $356K in Agena integration costs; management cites FX, labor, and material headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-018743","json":"https://secwatch.observer/filing/0001437749-22-018743.json","markdown":"https://secwatch.observer/filing/0001437749-22-018743.md","text":"https://secwatch.observer/filing/0001437749-22-018743.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/724004/000143774922018743/0001437749-22-018743-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/724004/000143774922018743/mlab20220803_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T04:36:51.331263+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}